- Home
- GYRE vs TWO Comparison
GYRE vs TWO Comparison
Compare GYRE & TWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- TWO
- Stock Information
- Founded
- GYRE 2002
- TWO 2009
- Country
- GYRE United States
- TWO United States
- Employees
- GYRE N/A
- TWO N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- TWO Real Estate Investment Trusts
- Sector
- GYRE Health Care
- TWO Real Estate
- Exchange
- GYRE Nasdaq
- TWO Nasdaq
- Market Cap
- GYRE 897.1M
- TWO 1.1B
- IPO Year
- GYRE N/A
- TWO 2009
- Fundamental
- Price
- GYRE $7.90
- TWO $10.11
- Analyst Decision
- GYRE Strong Buy
- TWO Buy
- Analyst Count
- GYRE 1
- TWO 8
- Target Price
- GYRE $18.00
- TWO $12.50
- AVG Volume (30 Days)
- GYRE 96.3K
- TWO 1.8M
- Earning Date
- GYRE 11-12-2025
- TWO 10-27-2025
- Dividend Yield
- GYRE N/A
- TWO 15.45%
- EPS Growth
- GYRE N/A
- TWO N/A
- EPS
- GYRE 0.02
- TWO N/A
- Revenue
- GYRE $102,189,000.00
- TWO $257,735,000.00
- Revenue This Year
- GYRE $18.39
- TWO N/A
- Revenue Next Year
- GYRE $48.26
- TWO N/A
- P/E Ratio
- GYRE $469.46
- TWO N/A
- Revenue Growth
- GYRE N/A
- TWO N/A
- 52 Week Low
- GYRE $6.11
- TWO $9.50
- 52 Week High
- GYRE $19.00
- TWO $14.28
- Technical
- Relative Strength Index (RSI)
- GYRE 51.30
- TWO 50.88
- Support Level
- GYRE $7.55
- TWO $9.97
- Resistance Level
- GYRE $8.56
- TWO $10.58
- Average True Range (ATR)
- GYRE 0.51
- TWO 0.18
- MACD
- GYRE -0.01
- TWO 0.02
- Stochastic Oscillator
- GYRE 57.14
- TWO 41.98
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About TWO Two Harbors Investment Corp
Two Harbors Investment Corp is a real estate investment trust focused on investing in, financing, and managing residential mortgage-backed securities, or RMBS; residential mortgage loans; mortgage servicing rights; and commercial real estate. The majority of the company's investment portfolio is split between agency RMBS purchased from government-sponsored enterprises and nonagency RMBS. Two Harbors derives nearly all of its revenue in the form of interest income collected from its investments. The majority of this income is generated by available-for-sale securities, while residential mortgage loans held for investment in securitization trusts also contribute a sizable amount.